Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.9K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Potent Anti-Glioblastoma Effects of Next-Generation MNK Inhibitors.

Cancers·2026
Same author

Simvastatin Treatment in Patients with Liver Cirrhosis: a Phase II Randomized Placebo Controlled Trial Shows Reduction in IL-6 Levels.

Cancer prevention research (Philadelphia, Pa.)·2026
Same author

SLFN5 restrains type I interferon responses and promotes glioblastoma via its N-terminal Schlafen core domain.

Communications biology·2026
Same author

Multi-omics analysis reveals LARP1 as a key integrator of translation and metabolism in AML.

Oncogenesis·2026
Same author

Measurable residual disease testing in acute myeloid leukemia: current state, foundational models, and tools for future development.

Cancer metastasis reviews·2026
Same author

Development of a SIN1 Targeting Inhibitor as a Novel Therapeutic Approach for the Treatment of Malignancies.

Molecular cancer therapeutics·2025

相关实验视频

Updated: Jan 13, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

623

睡眠12调制和向在急性髓性白血病中的目标.

Jamie N Guillen Magaña1, Markella Zannikou1,2, Aneta Baran1,2,3

  • 1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.

Cancer research communications
|October 28, 2025
PubMed
概括

这项研究揭示了Schlafen 12 (SLFN12) 在急性髓性白血病 (AML) 发展中的关键作用. 针对SLFN12的Velcrin化合物显示出希望作为AML的新疗法策略.

更多相关视频

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.4K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.6K

相关实验视频

Last Updated: Jan 13, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

623
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.4K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.6K

科学领域:

  • 分子生物学分子生物学
  • 癌症研究 癌症研究
  • 血液学 血液学 血液学

背景情况:

  • 施拉芬 (SLFN) 基因家族,包括SLFN12,包括干扰素调节的基因,涉及到细胞过程.
  • 白血病发生,特别是急性髓性白血病 (AML),需要对推动癌症进展的分子机制有更深入的了解.
  • 确定新的治疗点对于改善AML治疗结果至关重要.

研究的目的:

  • 研究SLFN12在急性髓性白血病 (AML) 的发展中的作用.
  • 为了评估velcrins的治疗潜力,小分子调节SLFN12活性,在AML.
  • 确定SLFN12作为AML的潜在治疗点.

主要方法:

  • 使用AML细胞模型检查SLFN12在白血病发生中的功能.
  • 评估了velcrin治疗对SLFN12稳定性和用基化酶3A/3B复合形成的影响.
  • 评估了velcrins对AML细胞生长,细胞亡和克隆性能力的影响.
  • 在小鼠AML异种移植模型中测试了velcrin的疗效.

主要成果:

  • 韦尔克林治疗稳定了SLFN12,并在AML细胞中促进了其与二酶3A/3B的复合形成.
  • 这些分子变化与白血病细胞显著增长抑制和亡诱导相关.
  • 韦尔克林抑制了原始白血病祖先的克隆性潜力.
  • 在AML的小鼠模型中,使用velcrins的治疗显著延长了生存时间.

结论:

  • SLFN12在急性髓性白血病的发病过程中发挥着重要作用.
  • 维尔克林通过向SLFN12显示出强大的抗白血病活性.
  • 这些发现凸显了SLFN12作为AML的一个有前途的治疗点,而velcrins代表了一个潜在的新疗法策略.